Rosso R, Campora E, Cetto G, Fosser V, Marangolo M, Oliva C
Department of Medical Oncology, Instituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Anticancer Res. 1991 Mar-Apr;11(2):937-9.
The efficacy of the serotonin antagonist ondansetron (GR38032F, Glaxo) was evaluated in the prevention of nausea and vomiting induced by combinations containing cyclophosphamide (CTX) greater than or equal to 600 mg/m2 IV day. At their first treatment course, 55 patients (10 males, 45 females) median age 55 years (range 31-76) were given ondansetron 8 mg orally tds for a minimum of 3 to a maximum of 5 days. 54 patients were evaluable. Complete and major control of acute (day 1) emesis was observed in 94.5% of patients and acute nausea was graded as absent or mild in 83.3% of cases. Complete and major control of emesis improved on subsequent study days from 96.1% on study day 2 to 100% on study day 5. Side effects were mild. Ondansetron is a safe and effective antiemetic drug.
评估了5-羟色胺拮抗剂昂丹司琼（GR38032F，葛兰素公司生产）对预防静脉注射环磷酰胺（CTX）剂量大于或等于600mg/m²/日的联合化疗方案所致恶心和呕吐的疗效。在首次治疗疗程中，55例患者（男性10例，女性45例），中位年龄55岁（范围31 - 76岁），口服昂丹司琼8mg，每日3次，至少服用3天，最多服用5天。54例患者可进行评估。94.5%的患者急性（第1天）呕吐得到完全和主要控制，83.3%的病例急性恶心分级为无或轻度。在随后的研究日，呕吐的完全和主要控制率从研究日2的96.1%提高到研究日5的100%。副作用轻微。昂丹司琼是一种安全有效的止吐药物。
